CSIMarket Company Name, Ticker, Suppliers, else..
Ocular Therapeutix Inc   (NASDAQ: OCUL)
Other Ticker:  
 


 

Ocular Therapeutix Inc

OCUL's Financial Statements and Analysis



Ocular Therapeutix Inc increased third quarter of 2025 net loss per share of $-0.38 compare to net loss per share of $-0.22 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.39 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ -0.38 $  15 Mill
$-0.16     $-1M     -5.71 %



Ocular Therapeutix Inc 's Revenue fell by -5.71 % in third quarter of 2025 (Sep 30 2025) year on year, to $15 million and advanced by 8.06 % sequentially.


Ocular Therapeutix Inc is

More on OCUL's Income Statement



Ocular Therapeutix Inc in the third quarter of 2025 recorded net loss of $-69.418 million, an increase from net loss of $-36.493 million in III. Quarter a year ago.

Sequentially net loss advanced

More on OCUL's Growth

Ocular Therapeutix Inc Inventories
Inventories grew by 45.03 % to $3 million from III. Quarter a year ago, sequentially inventories rose by 14.77 %. In Sep 30 2025 company's net cash and cash equivalents decreased by $-46 million, capital expenditures fell by -0.0896,633.71%, to $-6 millions compare to same quarter a year ago

More on OCUL's Cash flow Statement


Ocular Therapeutix Inc does not pay out common stock dividend.

In trailing twelve-month period Ocular Therapeutix Inc payed $ -1.03 cash per share, on a free-cash flow basis .

Book value fell by -20.79 % sequentially to $1.40 per share, -27.42% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.40 per share from $ 1.77.

Company issued 11.33 million shares or 6.56 % in Sep 30 2025.


• More on OCUL's Dividends

 Market Capitalization (Millions) 2,078
 Shares Outstanding (Millions) 184
 Total Debt (Millions $) 71
 Revenue (TTM) (Millions $) 56
 Net Income (TTM) (Millions $) -250
 Cash Flow (TTM) (Millions $) -82
 Capital Exp. (TTM) (Millions $) -9
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 103




Ocular Therapeutix Inc does not pay out common stock dividend.

In trailing twelve-month period Ocular Therapeutix Inc had negative $ -1.03 cash flow per share, on a free-cash flow basis .

Book value fell by -20.79 % sequentially to $1.40 per share, -27.42% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.40 per share from $ 1.77.

Company issued 11.33 million shares or 6.56 % in Sep 30 2025.


• More on OCUL's Balance Sheets

 Market Capitalization (Millions) 2,078
 Shares Outstanding (Millions) 184
 Total Debt (Millions $) 71
 Revenue (TTM) (Millions $) 56
 Net Income (TTM) (Millions $) -250
 Cash Flow (TTM) (Millions $) -82
 Capital Exp. (TTM) (Millions $) -9
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 103
   


  News about Ocular Therapeutix Inc Earnings

Ocular Therapeutix Inc Reports Double-Digit Revenue Growth in First Quarter of 2024

Ocular Therapeutix Inc, a biopharmaceutical company focused on developing innovative therapies for eye diseases, has seen fluctuations in its stock performance over the past year. Despite a 23.71% drop in the stock price over the past 5 trading days and a 5.17% decrease from a year before, the stock is currently trading 15.5% above its 52-week average on the NASDAQ.
While the company's revenue has increased by 10.468% in the most recent fiscal period to $14.77 million, Ocular Therapeutix Inc has reported a shortfall per share of $-0.49. This represents a significant increase in the shortfall compared to previous quarters. For the January to March 31, 2024 period, the company realized a net shortfall of $...

2. Struggling Ocular Therapeutix Inc Reports Higher Losses Despite Revenue Growth

Ocular Therapeutix Inc (OCUL) seems to be facing some significant challenges based on its recent financial performance. In the fiscal period from October to December 31, 2023, the company reported a loss per share of $-0.27, compared to $-0.19 from the previous year. This represents a surge in losses from the prior reporting season where the loss per share was $-0.25.
Furthermore, despite a growth in revenue by 5.158% to $14.80 million from $14.08 million in the same reporting season a year prior, there was a sequential decrease in revenue of -1.85% from $15.08 million. This indicates a potential decline in demand or challenges in maintaining consistent revenue growth.
The net loss for the October t...

Ocular Therapeutix Inc Shoots for Success: Achieves Outstanding Financial Milestones Amidst Challenging Times

Ocular Therapeutix Inc, a major pharmaceutical preparations company, showed promising results in their most recent fiscal period. Notably, the company decreased their loss per share, with a significant improvement of $0.06 compared to the same reporting period a year prior. Furthermore, their EPS improved by $0.01 per share compared to the preceding reporting period. These figures indicate a positive trend in the company's financial performance.
One of the key highlights of Ocular Therapeutix Inc's recent performance is the rapid increase in revenue. The company experienced a significant growth rate of 26.043%, with revenue reaching $15.08 million in the most recent reporting period, compared to $11.97 m...

Ocular Therapeutix Inc Shows Revenue Surge Amidst Widening Deficit Over Q2 2023 Fiscal Period


Introduction
Ocular Therapeutix Inc (NASDAQ: OCUL) recently announced a substantial increase in revenue for the most recent fiscal period, showcasing a positive sign of growth for the biopharmaceutical company. However, the company's net loss has widened, presenting challenges in the road to profitability. As investors eagerly await the next financial report, it is important to assess Ocular Therapeutix's future performance, taking into consideration its recent stock performance and position in the market.
Revenue Surge and Widening Deficit
In the most recent fiscal period, Ocular Therapeutix Inc reported a revenue surge of 23.806%, with total revenue reaching $15.19 million compared to the ...


Date modified: 2025-11-04T21:01:59+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.